ATE454449T1 - Menschlicher rezeptor h4-1bb - Google Patents

Menschlicher rezeptor h4-1bb

Info

Publication number
ATE454449T1
ATE454449T1 AT94928141T AT94928141T ATE454449T1 AT E454449 T1 ATE454449 T1 AT E454449T1 AT 94928141 T AT94928141 T AT 94928141T AT 94928141 T AT94928141 T AT 94928141T AT E454449 T1 ATE454449 T1 AT E454449T1
Authority
AT
Austria
Prior art keywords
receptor protein
protein
human
receptor
cells
Prior art date
Application number
AT94928141T
Other languages
English (en)
Inventor
Byoung S Kwon
Original Assignee
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22404839&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE454449(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Indiana Res & Tech Corp filed Critical Univ Indiana Res & Tech Corp
Application granted granted Critical
Publication of ATE454449T1 publication Critical patent/ATE454449T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Radio Relay Systems (AREA)
  • Mobile Radio Communication Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT94928141T 1993-09-16 1994-09-15 Menschlicher rezeptor h4-1bb ATE454449T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12279693A 1993-09-16 1993-09-16
PCT/US1994/010457 WO1995007984A1 (en) 1993-09-16 1994-09-15 Human receptor h4-1bb

Publications (1)

Publication Number Publication Date
ATE454449T1 true ATE454449T1 (de) 2010-01-15

Family

ID=22404839

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94928141T ATE454449T1 (de) 1993-09-16 1994-09-15 Menschlicher rezeptor h4-1bb

Country Status (11)

Country Link
US (3) US8026353B2 (de)
EP (1) EP0719329B1 (de)
JP (2) JPH09503911A (de)
KR (2) KR100244960B1 (de)
AT (1) ATE454449T1 (de)
AU (1) AU697482B2 (de)
CA (2) CA2429027C (de)
DE (1) DE69435261D1 (de)
ES (1) ES2341631T3 (de)
NZ (1) NZ273838A (de)
WO (1) WO1995007984A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US7211259B1 (en) 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
US7138500B1 (en) 1993-05-07 2006-11-21 Immunex Corporation Antibodies to human 4-1BB
JPH09503911A (ja) 1993-09-16 1997-04-22 インディアナ・ユニバーシティー・ファウンデーション ヒトｈ４−１ｂｂ受容体
DK0766745T3 (da) * 1995-04-08 2002-11-25 Lg Chemical Ltd Monoklonalt antistof, som er specifikt for humant 4-1BB samt cellelinje, som producerer dette
US5874240A (en) * 1996-03-15 1999-02-23 Human Genome Sciences, Inc. Human 4-1BB receptor splicing variant
AU5710996A (en) * 1996-03-15 1997-10-01 Human Genome Sciences, Inc. Human 4-1bb receptor splicing variant
RU2192281C2 (ru) * 1996-10-11 2002-11-10 Бристол-Маерс Сквибб Компани Способы и композиции для иммуномодуляции
HUP0102046A3 (en) * 1998-07-15 2006-02-28 Merckle Gmbh Utilization of cd137 in order to promote the proliferation of peripheral monocytes
DK1234031T3 (en) 1999-11-30 2017-07-03 Mayo Foundation B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE
US7651686B2 (en) 2001-10-09 2010-01-26 Mayo Foundation For Medical Education And Research Enhancement of immune responses by 4-1bb-binding agents
US20040109847A1 (en) * 2002-07-15 2004-06-10 Lieping Chen Treatment and prophylaxis with 4-1BB-binding agents
EP1575672A2 (de) * 2002-12-16 2005-09-21 Herbert Schwarz Verwendung von cd137-antagonisten zur behandlung von tumoren
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US20070253961A1 (en) * 2004-06-09 2007-11-01 Ulsan Industrial Education Foundation Pharmaceutical Composition Comprising the Anti-4-1Bb Antibody for Treating or Preventing Rheumatoid Arthritis
DK1810026T3 (en) 2004-10-06 2018-07-16 Mayo Found Medical Education & Res B7-H1 AND PD-1 FOR TREATMENT OF RENAL CELL CARCINOM
US20060182744A1 (en) * 2005-02-15 2006-08-17 Strome Scott E Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
KR20140133958A (ko) * 2005-10-21 2014-11-20 엘에프비 유에스에이, 인크. 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및 사용 방법
EP2279003A4 (de) * 2008-05-01 2013-04-03 Gtc Biotherapeutics Inc Anti-cd137-antikörper als mittel zur behandlung von entzündlichen erkrankungen
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
WO2011149025A1 (ja) * 2010-05-28 2011-12-01 株式会社上野忠 経口用体温上昇剤
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
KR20140004174A (ko) 2011-01-18 2014-01-10 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 치료를 위한 조성물 및 방법
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
ES2714708T3 (es) 2013-10-01 2019-05-29 Mayo Found Medical Education & Res Procedimientos para el tratamiento de cáncer en pacientes con niveles elevados de Bim
AU2015244039B2 (en) 2014-04-07 2021-10-21 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
WO2016014148A1 (en) 2014-07-23 2016-01-28 Mayo Foundation For Medical Education And Research Targeting dna-pkcs and b7-h1 to treat cancer
JP6961490B2 (ja) 2015-04-08 2021-11-05 ノバルティス アーゲー Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法
WO2017075045A2 (en) 2015-10-30 2017-05-04 Mayo Foundation For Medical Education And Research Antibodies to b7-h1
BR112019006781A2 (pt) 2016-10-07 2019-07-30 Novartis Ag receptores de antígeno quiméricos para o tratamento de câncer
EP3571230A4 (de) 2017-01-20 2020-12-16 Magenta Therapeutics, Inc. Zusammensetzungen und verfahren zur abreicherung von cd137+-zellen
AU2018301393B2 (en) 2017-07-11 2025-02-27 Compass Therapeutics Llc Agonist antibodies that bind human CD137 and uses thereof
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
EP3713961A2 (de) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137-antikörper und tumorantigenbindende antikörper sowie deren verwendung
WO2020092839A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP3873540A4 (de) 2018-10-31 2022-07-27 Mayo Foundation for Medical Education and Research Verfahren und materialien zur behandlung von krebs
KR20220145859A (ko) 2020-02-28 2022-10-31 상하이 헨리우스 바이오테크, 인크. 항cd137 작제물, 다중 특이적 항체 및 그 용도
KR20220148209A (ko) 2020-02-28 2022-11-04 상하이 헨리우스 바이오테크, 인크. 항cd137 작제물 및 그 용도
CN114605541B (zh) * 2021-08-26 2023-08-29 北京大学深圳研究生院 一种抗4-1bb纳米抗体、编码基因及应用
WO2026085300A1 (en) 2024-10-16 2026-04-23 Flagship Pioneering Innovations Vii, Llc Compositions and methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560649A (en) 1981-10-15 1985-12-24 Cornell Research Foundation Assaying for hLH or hCG with immobilized hormone receptors
US4837306A (en) * 1985-02-25 1989-06-06 The Ontario Cancer Institute Method for selecting hybridomas producing antibodies specific to the P-glycoprotein cell suface antigen and a cDNA clone encoding the C-terminal portion of the antigen
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US7211259B1 (en) * 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
US7138500B1 (en) * 1993-05-07 2006-11-21 Immunex Corporation Antibodies to human 4-1BB
US5674704A (en) 1993-05-07 1997-10-07 Immunex Corporation Cytokine designated 4-IBB ligand
JPH09503911A (ja) 1993-09-16 1997-04-22 インディアナ・ユニバーシティー・ファウンデーション ヒトｈ４−１ｂｂ受容体
DK0766745T3 (da) * 1995-04-08 2002-11-25 Lg Chemical Ltd Monoklonalt antistof, som er specifikt for humant 4-1BB samt cellelinje, som producerer dette

Also Published As

Publication number Publication date
JP2006149389A (ja) 2006-06-15
AU7729494A (en) 1995-04-03
DE69435261D1 (de) 2010-02-25
CA2172165A1 (en) 1995-03-23
US20070117161A1 (en) 2007-05-24
US20020168719A1 (en) 2002-11-14
WO1995007984A1 (en) 1995-03-23
CA2429027C (en) 2011-04-05
CA2429027A1 (en) 1995-03-23
EP0719329A1 (de) 1996-07-03
KR100271382B1 (en) 2000-11-15
KR100244960B1 (ko) 2000-02-15
EP0719329B1 (de) 2010-01-06
US20080312418A1 (en) 2008-12-18
CA2172165C (en) 2003-12-02
US8026353B2 (en) 2011-09-27
AU697482B2 (en) 1998-10-08
JPH09503911A (ja) 1997-04-22
ES2341631T3 (es) 2010-06-23
NZ273838A (en) 1997-09-22

Similar Documents

Publication Publication Date Title
ATE454449T1 (de) Menschlicher rezeptor h4-1bb
Lane et al. Soluble CD40 ligand can replace the normal T cell-derived CD40 ligand signal to B cells in T cell-dependent activation.
Luescher et al. CD8 modulation of T-cell antigen receptor–ligand interactions on living cytotoxic T lymphocytes
Welte et al. Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein
Fangmann et al. Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides.
US5747037A (en) Anti-GP39 antibodies
Olsson et al. Bidirectional activating signals between Trypanosoma brucei and CD8+ T cells: A trypanosome‐released factor triggers interferon‐γ production that stimulates parasite growth
AU784634B2 (en) B7-H1, a novel immunoregulatory molecule
Bonnefoy et al. The low-affinity receptor for IgE (CD23) on B lymphocytes is spatially associated with HLA-DR antigens.
CA2246352A1 (en) Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
US5869049A (en) Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
Bikah et al. A role for CD5 in cognate interactions between T cells and B cells, and identification of a novel ligand for CD5.
KR940007179A (ko) 시디40 (cd40)을 위한 수용성 리간드
CA2146895A1 (en) Ctla4/cd28ig hybrid fusion proteins
DK0741784T3 (da) Ligand (ACT-4-L) til en receptor på overfladen af aktiverede CD4+ T-celler
JP2007126481A (ja) Ｔ細胞の不応答性を調節する方法
Csencsits et al. Contrasting alloreactive CD4+ and CD8+ T cells: there's more to it than MHC restriction
US20050163780A1 (en) Method for prolonged suppression of humoral immune response to a thymus-dependent antigen
JP2004537500A (ja) 腫瘍の増殖の阻害および免疫応答の増強のための方法および組成物
WO2001036630A2 (en) Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same
Mortara et al. Therapy‐induced antitumor vaccination by targeting tumor necrosis factor‐α to tumor vessels in combination with melphalan
Koide et al. Augmentation of Human Natural Cell-Mediated Cytotoxicity by a Soluble Factor: I. Production of N-Cell-Activating Factor (NAF)
AU734853B2 (en) Methods of prolonged suppression of humoral immunity
Van Seventer et al. Mechanism of inhibition and induction of cytolytic activity in cytotoxic T lymphocytes by CD3 monoclonal antibodies.
Bromberg The biology of CD2: adhesion, transmembrane signal, and regulatory receptor of immunity

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties